AD Lib

ID: 10548
Title:Quetiapine for Agitation or Psychosis in Patients With Dementia and Parkinsonism.
Publication Year: 2007
Format(s): Journal Article , Funded Research
Language(s): English
Audience(s): Physicians , Psychiatrists , Neurologists , Geriatricians
Author(s): Kurlan, R.; , Cummings, J.; , Raman, R.; , Thal, L.
Source: Neurology. 68: 1356-1363. April 24, 2007.

Abstract: The purpose of this study was to assess the efficacy and tolerability of the antipsychotic drug quetiapine for agitation or psychosis in patients with dementia and parkinsonism. The design was a multicenter randomized, double-blind, placebo-controlled, parallel-groups clinical trial involving 40 patients with dementia with Lewy bodies (n=23), Parkinson’s disease (PD) with dementia (n=9), or Alzheimer’s disease (AD) with parkinsonian features (n=8). The main outcome measure for efficacy was change in the Brief Psychiatric Rating Scale (BPRS) from baseline to 10 weeks of therapy. Tolerability was measured with the Unified PD Rating Scale over the same time period. The trial was confounded by the need for a design change and incomplete recruitment. No significant changes in the primary or secondary outcome measures of efficacy were observed. An unexpectedly large placebo effect, inadequate dosage (mean 120 mg/day), and inadequate power may have contributed to the lack of demonstrable benefit. Quetiapine was generally well-tolerated and did not worsen parkinsonism, but was associated with a trend toward a decline in daily functioning. This study failed to demonstrate a pharmacologic effect of quetiapine in treating agitation or psychosis in patients with dementia and parkinsonism. 1 figure, 3 tables, 33 references. (AA-M).

Major Descriptor(s): DEMENTIA , PARKINSONISM , PARKINSONS-DISEASE , ALZHEIMERS-DISEASE , DEMENTIA-WITH-LEWY-BODIES , PSYCHOTROPIC-DRUGS , DRUG-EFFECTS , DRUG-EVALUATION , CLINICAL-TRIALS
Minor Descriptor(s):

New AD Lib Search